Eli Lilly stock price forecast: $850–$900 range as LLY declines 3.78%

Traders Union
All News
Financial News
Eli Lilly slides 3.78% today

Highlights

Eli Lilly acquired Kelonia Therapeutics for up to $7 billion, gaining access to Kelonia's CAR-T cancer therapy and expanding into genetic and cell therapies.
Recent FDA requests for additional safety data on Eli Lilly’s obesity pill created short-term uncertainty amid institutional investor accumulation.
Eli Lilly shares trade below key averages with strong downside momentum; the forecasted range is $850 to $900, with a high probability of further declines short-term.

Portfolio expansion and FDA inquiry drive mixed investor sentiment

On April 20, 2026, Eli Lilly announced the acquisition of Kelonia Therapeutics in a transaction valued at up to $7 billion, gaining rights to Kelonia's CAR-T cancer therapy in development and expanding its portfolio in genetic and cell therapies. This deal followed earlier acquisitions of Verve Therapeutics and Orna Therapeutics, further broadening its pipeline in in vivo genetic medicines. Institutional investor interest was recorded as Whittier Trust Co. increased its stake in Eli Lilly, and recent FDA requests for additional liver injury and cardiovascular data for the company's newly approved obesity pill introduced some short-term uncertainty, though price action has remained under broader selling pressure.

Momentum signals, resistance barriers reinforce downward trajectory

LLY is trading below the SMA-20 ($920.91), SMA-50 ($971.36), and just under the SMA-200 ($906.05). The Ichimoku Kijun on the D1 timeframe is at $940.11, marking immediate resistance. MACD indicates a strong sell signal, while ADX is neutral, showing limited trend strength but clear downside momentum. RSI and Stoch RSI both signal additional selling, with CCI on lower timeframes near oversold territory; BBP on the daily chart is overbought but intraday readings confirm seller dominance. Today's gap lower and close to the daily low align with high volatility and persistent downward momentum.

Downside bias expected unless resistance break triggers reversal

In the short term, the typical volatility band is expected to be between $850 and $900 over the next five trading days. There is a low probability (less than 20%) of a sustained price increase from current levels, making further declines more likely. The base scenario projects LLY consolidating within the $850 to $900 range. A move above the $940 resistance could trigger a bullish reversal, while a drop below $850 may open up additional downside risk if support fails.

Anton Kharitonov, expert at Traders Union, sees a technically weak setup for Eli Lilly as shares remain under broad selling pressure and below key moving averages. He believes recent acquisitions highlight strategic ambition, but near-term sentiment stays negative amid regulatory uncertainty and poor momentum signals. The analyst stays cautious and favors a defensive stance until the $940 level is reclaimed. "Base case remains sideways to lower — until bulls break resistance, sellers control the field."

Previously it was reported that Eli Lilly shares were under persistent downside pressure despite expansions in its obesity treatment portfolio, with technical signals highlighting heightened bearish momentum. The latest developments—including the Kelonia Therapeutics acquisition and regulatory uncertainties—reinforce these bearish conditions, suggesting investors should closely watch the $850 support level for any signs of a reversal or deeper declines.

Source of Data: LLY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.